Biotech · Private company
OSE Immunotherapeutics
Track this companyFree. Adds OSE Immunotherapeutics to your Dealase workspace and tells you when its record changes.
Clinical trials21 recruiting or active
Pipeline programs6From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline6
- DocetaxelPhase 3 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- DocetaxelPhase 3 · Patients With Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- NGS HLAA2 assayPhase 3 · Patients With Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- OSE2101Phase 3 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- OSE2101Phase 3 · Patients With Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- PemetrexedPhase 3 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials2
- Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint InhibitorPHASE3 · RECRUITING · started Dec 3, 2024ClinicalTrials.gov NCT06472245 · fetched Nov 12, 2026
- OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor FailurePHASE3 · TERMINATED · started Feb 12, 2016ClinicalTrials.gov NCT02654587 · fetched Nov 12, 2026